Literature DB >> 26507928

Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.

Ronald de Vries1, Mike Huang2, Nini Bode1, Purvi Jejurkar3, Jan de Jong4, Juthamas Sukbuntherng3, Luc Sips1, Naidong Weng2, Philip Timmerman1, Tom Verhaeghe1.   

Abstract

Ronald de Vries graduated in Organic and Analytical Chemistry at the Free University of Amsterdam, The Netherlands. After working in a Contract Laboratory (CRO) for 7 years, he joined Janssen R&D in 1998. At Janssen R&D, Belgium, Ronald worked in the bioanalytical department that supports both clinical and nonclinical bioanalysis. In this department he had several roles, such as providing the bioanalytical support for various drug development programs and leading the method establishment group. He has done numerous global assay transfers to/from Janssen from/to other laboratories and plays an important role in the introduction and application of new technologies and applied innovation in the department. In 2014 he started in the drug metabolism and pharmacokinetics department of Janssen R&D, where his main tasks are in vivo and in vitro metabolite identification using high resolution MS and Radiodetection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26507928     DOI: 10.4155/bio.15.159

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  5 in total

1.  Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.

Authors:  Silvia Maria Lavezzi; Jan de Jong; Martine Neyens; Paula Cramer; Fatih Demirkan; Graeme Fraser; Nancy Bartlett; Marie-Sarah Dilhuydy; Javier Loscertales; Abraham Avigdor; Simon Rule; Olga Samoilova; Andre Goy; Siddhartha Ganguly; Mariya Salman; Angela Howes; Michelle Mahler; Giuseppe De Nicolao; Italo Poggesi
Journal:  Pharm Res       Date:  2019-05-01       Impact factor: 4.200

2.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

3.  Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

Authors:  Chaitra S Ujjani; Sin-Ho Jung; Brandelyn Pitcher; Peter Martin; Steven I Park; Kristie A Blum; Sonali M Smith; Myron Czuczman; Matthew S Davids; Ellis Levine; Lionel D Lewis; Scott E Smith; Nancy L Bartlett; John P Leonard; Bruce D Cheson
Journal:  Blood       Date:  2016-10-03       Impact factor: 22.113

4.  Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.

Authors:  Jan de Jong; Anna Mitselos; Wojciech Jurczak; Raul Cordoba; Carlos Panizo; Tomasz Wrobel; Monika Dlugosz-Danecka; James Jiao; Juthamas Sukbuntherng; Daniele Ouellet; Peter Hellemans
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 5.  Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.

Authors:  Rong Dong; Youyou Yan; Xiaokang Zeng; Nengming Lin; Biqin Tan
Journal:  Drug Des Devel Ther       Date:  2022-09-20       Impact factor: 4.319

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.